Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer
Authors:
- D M ClarkeDCD M Clarke
- J G BaustJBJ G Baust
- J M BaustJBJ M Baust
- 13 February 2007
- journal article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 10 (2) , 175-184
Abstract
Adjuvant therapies contribute to the successful treatment of cancer. Our previous reports have shown that combining cryoablation with cytotoxic agents enhances cell death. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytotoxic agent that preferentially induces apoptosis in a variety of human cancer cells. Human prostate cancer cells (PC-3) are resistant to many cytodestructive agents, including cryoablation and TRAIL. Here, we evaluated the effects of TRAIL combined with cryoablation on PC-3 and normal prostate (RWPE-1) cell death. Exposure of PC-3 cells to freezing (-10°C) or TRAIL (500ng/ml) results in minimal cell death, whereas a complete loss of viability is observed with the simultaneous combination. The synergistic effect was found to be due to a marked increase in apoptosis. Western blot analysis revealed a significant level of caspase-8 and -3 cleavage between 12 and 24 h post-exposure. Caspase activation assays provided similar results and also indicated a role for caspase-9. Inhibitors to caspase-8 and -9 along with a pan-caspase inhibitor were incorporated to determine which pathway was necessary for the combined efficacy. Inhibition of caspase-8 significantly blocked the combination-induced cell death compared to cells that did not receive the inhibitor (63% compared to 10% viable). The addition of the caspase-9 inhibitor resulted in only a minimal protection. Importantly, the combination was not effective when applied to normal prostate cells. The results describe a novel therapeutic model for the treatment of prostate cancer and provide support for future in vivo studies.Keywords
This publication has 37 references indexed in Scilit:
- Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating AgentsJournal of Clinical Oncology, 2005
- Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistanceJournal of Cellular Biochemistry, 2005
- Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitorApoptosis, 2005
- Cryosurgical ablation of the prostateCancer, 2005
- Salvage cryosurgery for locally recurrent prostate cancer following radiotherapyProstate Cancer and Prostatic Diseases, 2004
- Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathwayOncogene, 2004
- Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathwayOncogene, 2004
- Treatment of Organ Confined Prostate Cancer with Third Generation Cryosurgery: Preliminary Multicenter ExperienceJournal of Urology, 2003
- PROGRESSION IN AND SURVIVAL OF PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER (T3) TREATED WITH RADICAL PROSTATECTOMY AS MONOTHERAPYJournal of Urology, 1998
- CryosurgeryCritical Reviews in Oncology/Hematology, 1996